Intrauterine cytomegalovirus infection and glycoprotein B genotypes

J F Bale1, J R Murph, G J Demmler

  • 1Division of Pediatric Neurology, Primary Children's Medical Center, Salt Lake City, UT 84113, USA. pcjbale@ihc.com

Insights

Cytomegalovirus (CMV) glycoprotein B (gB) genotypes were analyzed in infants with intrauterine infections. The gB 3 genotype was more frequent in asymptomatic cases, but did not impact neurodevelopmental outcomes.

Area of Science:

  • Virology
  • Genetics
  • Neonatal Medicine

Background:

  • Cytomegalovirus (CMV) strains exhibit genetic variations in glycoprotein B (gB; gpUL55).
  • Emerging evidence suggests a link between gB genotype and acquired CMV infection outcomes.
  • The role of gB genotype in intrauterine CMV infection outcomes requires further investigation.

Purpose of the Study:

  • To investigate the association between Cytomegalovirus (CMV) glycoprotein B (gB) genotypes and clinical/neurodevelopmental outcomes in infants with intrauterine CMV infections.

Main Methods:

  • Analysis of CMV strains from 56 infants with culture-confirmed intrauterine CMV infections.
  • Genotyping of the CMV gB gene (gpUL55) for 53 strains.
  • Comparison of gB genotypes with neonatal clinical features and neurodevelopmental assessments.

Main Results:

  • Fifty-three (95%) CMV strains were successfully genotyped.
  • Prevalent gB genotypes included type 1 (50%), type 3 (23%), type 2 (18%), and type 4 (4%).
  • The gB 3 genotype was more common in asymptomatic infants (P=.004), though geographic factors may play a role.
  • No significant correlation was found between gB genotypes and neurodevelopmental outcomes.

Conclusions:

  • CMV gB genotype distribution varies among infants with intrauterine infections.
  • The gB 3 genotype may be associated with asymptomatic intrauterine CMV infections.
  • CMV gB genotype does not appear to influence the neurodevelopmental outcome of intrauterine CMV infection.